NCT00526812 is a Phase 1 clinical trial of RTA 744 in Glioma, sponsored by Biogen.

Who is sponsoring NCT00526812?

NCT00526812 is sponsored by Biogen.

What drugs are being tested in NCT00526812?

Interventions in NCT00526812: RTA 744, RTA 744 injection.

Is NCT00526812 still recruiting?

NCT00526812 is currently completed. Last updated 28 May 2025.

Last reviewed 2025-05-28 · How we verify

NCT00526812

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Completed Phase 1 Last updated 28 May 2025

What this trial tests

Phase 1 trial testing RTA 744 in Glioma in 54 participants. Completed.

Timeline

30 November 2005

Primary endpoint
1 December 2008

Quick facts

Lead sponsor	Biogen
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	30 November 2005
Primary completion	1 December 2008
Sites	4 locations across United States

Drugs / interventions tested

RTA 744 — full drug profile →
RTA 744 injection

Conditions studied

Glioma — all drugs for Glioma →

Sponsor

Biogen — full company profile →

Who can join

18 and older, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.
Dhiman A, Rana D, Benival D, Garkhal K. · · 2025 · cited 3× · PMID 39445563 · DOI 10.1080/20415990.2024.2415281

Verify or expand the search:

Other trials of RTA 744

Trials testing the same drug.

NCT00527410 — A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis · Phase 1 · terminated

Other recruiting trials for Glioma

Currently open trials in the same condition.

NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
NCT07450872 — Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors · recruiting
NCT07405372 — Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas · recruiting
NCT07338539 — BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM · Phase 2 · recruiting

Other Biogen trials

Trials by the same sponsor.

NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
NCT07444450 — A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy · Phase 3 · not yet recruiting
NCT07444489 — A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants · Phase 3 · not yet recruiting
NCT07444476 — A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years Wit · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00526812 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biogen
Last refreshed: 28 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00526812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing